Outlook Therapeutics (OTLK) said Friday it has regained compliance with Nasdaq's minimum bid price listing requirement.
The company said it was notified that it had regained compliance as the closing bid price of its shares had been at $1 per share or greater for 10 consecutive business days.
Shares of Outlook Therapeutics were 3.5% lower in Monday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments